PALISADE BIO, INC.

Palisade Bio reported its Q2 2026 financial results and announced the advancement of its lead clinical candidate, PALI-2108, into Phase 2 development for ulcerative colitis (UC) and Crohn’s disease (CD). The company expects to enroll the first patient for the Phase 2 ASCENTRA-UC trial in 2H 2026, with primary efficacy results anticipated in 2H 2027. An IND for the Phase 2 ASCENTRA-CD trial is also expected in 2H 2026. Despite an increased net loss of $10.6 million for the quarter, the company maintains a strong cash position of $125.2 million, sufficient to fund operations through key Phase 2 clinical readouts.

Palisade Bio, Inc. reported its second quarter 2026 financial results and provided a business update, highlighting the advancement of PALI-2108 into Phase 2 development for ulcerative colitis (UC) and Crohn’s disease (CD). The company expects to enroll the first patient for the Phase 2 ASCENTRA-UC trial in 2H 2026 and submit an IND for the Phase 2 ASCENTRA-CD trial in 2H 2026. For Q2 2026, Palisade Bio reported a net loss of $10.6 million, with increased R&D and G&A expenses, but maintains a strong cash position of $125.2 million, sufficient to fund operations through key Phase 2 clinical readouts expected in 2027 and 2028.

Palisade Bio reported a net loss of $10.57 million, or $(0.05) per share, for Q2 2026, compared to a net loss of $2.78 million, or $(0.58) per share, in Q2 2025. License revenue was $0.5 million for the quarter. The company ended Q2 2026 with $125.2 million in cash and cash equivalents, providing sufficient capital for at least one year. The company also increased its authorized common stock to 450 million shares and is advancing its lead clinical product candidate, PALI-2108, into Phase 2 clinical trials.

Palisade Bio, Inc. announced that its CEO, JD Finley, and President & Chief Medical Officer, Dr. Mitchell Jones, will participate in the Leerink Partners Therapeutics Forum on July 14-15, 2026. They will engage in one-on-one meetings with institutional investors to discuss the company's clinical development strategy, recent progress with PALI-2108, and upcoming milestones for its inflammatory bowel disease programs.

Palisade Bio announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PALI-2108. This clearance enables the initiation of the global Phase 2 ASCENTRA-UC clinical trial for patients with moderately to severely active ulcerative colitis. The company expects to begin patient enrollment in the second half of 2026, with primary efficacy results anticipated in the second half of 2027. Additionally, Palisade Bio plans to submit an IND for ASCENTRA-CD for Crohn's disease in the second half of 2026 and has partnered with PSI for the ASCENTRA-UC trial execution.

Palisade Bio stockholders approved an amendment to increase the total number of authorized shares of common stock from 300 million to 450 million shares. The company also appointed Jordan Zwick to its Board of Directors and Audit Committee, expanding the board to six members. Additionally, stockholders approved amended equity incentive and employee stock purchase plans, re-elected four directors, and ratified Baker Tilly US, LLP as the independent auditor for the fiscal year ending December 31, 2026.

Palisade Bio, Inc. announced the appointment of Robert Baltera and Jordan Zwick to its Board of Directors. These additions are expected to strengthen the board with extensive expertise in biotechnology leadership, strategic transactions, capital markets, and corporate governance. The company is continuing to advance its lead program, PALI-2108, a PDE4 inhibitor prodrug, toward Phase 2 clinical development for inflammatory bowel diseases.

Palisade Bio announced that its President and Chief Medical Officer, Dr. Mitchell Jones, will present at the New York Academy of Sciences symposium on June 9, 2026. The presentation will focus on fibrostenotic Crohn’s disease (FSCD) and the potential of the company's lead drug candidate, PALI-2108, a locally bioactivated PDE4 inhibitor prodrug. Dr. Jones will discuss the significant unmet need in FSCD, the biological mechanisms of intestinal fibrosis, and preclinical findings supporting PALI-2108's therapeutic approach. PALI-2108 has demonstrated positive results in Phase 1a and two Phase 1b clinical trials and is advancing towards Phase 2 studies.

Palisade Bio, Inc. announced that its CEO, JD Finley, and President & Chief Medical Officer, Dr. Mitchell Jones, will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 3:45 PM ET. A live webcast of the presentation will be available on the company's website, with a replay archived for a limited time. Additionally, management will be available for one-on-one meetings with qualified members of the investor community registered for the conference.

Palisade Bio reported its first quarter 2026 financial results and provided an update on its lead program, PALI-2108. The company plans to initiate a Phase 2 Ulcerative Colitis (UC) trial in Q3 2026 and a Phase 2 Crohn's Disease (CD) trial in Q1 2027, building on positive Phase 1a/b data. For Q1 2026, Palisade Bio reported a net loss of $9.6 million, with increased R&D and G&A expenses. The company maintains a strong balance sheet with $132.6 million in cash, expected to fund operations through key clinical readouts in 2027 and 2028.